Merck & Co has entered into a worldwide licensing deal with Opko Health’s ModeX Therapeutics unit for a vaccine candidate against Epstein-Barr virus (EBV) that could b
OPKO Health’s weekly growth hormone injection could be approvable in adults without need for further clinical trials, the company has told pharmaphorum.
US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone product (hGH-CTP), even though it has failed in a late stage trial in adul
The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio